Abstract
In this study, we compared the tumor-targeting properties, therapeutic efficacy, and tolerability of the humanized anti-CAIX antibody (hG250) labeled with either the α-emitter actinium-225 ((225)Ac) or the β(-)-emitter lutetium-177 ((177)Lu) in mice. BALB/c nude mice were grafted with human renal cell carcinoma SK-RC-52 cells and intravenously injected with 30 µg [(225)Ac] Ac-DOTA-hG250 ((225)Ac-hG250) or 30 µg [(177)Lu] Lu-DOTA-hG250 ((177)Lu-hG250), followed by ex vivo biodistribution studies. Therapeutic efficacy was evaluated in mice receiving 5, 15, and 25 kBq of (225)Ac-hG250; 13 MBq of (177)Lu-hG250; or no treatment. Tolerability was evaluated in non-tumor-bearing animals. High tumor uptake of both radioimmunoconjugates was observed and increased up to day 7 (212.8 ± 50.2 %IA/g vs. 101.0 ± 18.4 %IA/g for (225)Ac-hG250 and (177)Lu-hG250, respectively). Survival was significantly prolonged in mice treated with 15 kBq (225)Ac-hG250, 25 kBq (225)Ac-hG250, and 13 MBq (177)Lu-hG250 compared to untreated control (p < 0.05). Non-tumor-bearing mice that received single-dose treatment with 15 or 25 kBq (225)Ac-hG250 showed weight loss at the end of the experiment (day 126), and immunohistochemical analysis suggested radiation-induced nephrotoxicity. These results demonstrate the therapeutic potential of CAIX-targeted α-therapy in renal cell carcinoma. Future studies are required to find an optimal balance between therapeutic efficacy and toxicity.
